Sale!

Lung Cancer Panel 4 EGFRALK1ROS1METPD L1 Test

6,000 د.إ

-25%

The “Lung Cancer Panel 4 EGFRALK1ROS1METPD L1 Test” is a comprehensive genomic profiling assay performed at DNA Labs UAE, designed to identify specific genetic mutations and alterations in lung cancer patients. This panel targets key genes associated with lung cancer, including EGFR, ALK1, ROS1, MET, and PD-L1, which are crucial for personalized medicine and targeted therapy decisions. By analyzing these genes, oncologists can tailor treatment strategies to the individual’s genetic makeup, improving outcomes and minimizing unnecessary treatments. The test cost is 6000 AED, reflecting the sophisticated technology and expertise required to accurately identify these mutations. Conducted at DNA Labs UAE, a facility known for its advanced diagnostic capabilities and commitment to precision medicine, this test represents a significant step forward in the management and treatment of lung cancer, offering hope for more effective and personalized care.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

Lung Cancer Panel 4 EGFRALK1ROS1METPD L1 Test

Cost: AED 6000.0

Test Name:

Lung Cancer Panel 4 EGFRALK1ROS1METPD L1 Test

Components:

Paraffin embedded tissue blocks

Price:

AED 6000.0

Sample Condition:

Tumor tissue

Report Delivery:

5-7 days

Method:

FISH, Sanger Sequencing

Test Type:

Genetics

Doctor:

Oncology

Test Department:

Pre Test Information

Lung Cancer Panel 4 EGFRALK1ROS1METPD L1 Test can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details:

The Lung Cancer Panel 4 is a diagnostic test that analyzes five specific genetic mutations and biomarkers associated with lung cancer. The panel includes the following:

  1. EGFR (epidermal growth factor receptor) – EGFR mutations are found in a significant number of non-small cell lung cancers (NSCLC) and can be targeted by specific drugs.
  2. ALK1 (anaplastic lymphoma kinase) – ALK1 gene rearrangements are found in a small subset of NSCLC and can also be targeted by specific drugs.
  3. ROS1 (c-ros oncogene 1) – ROS1 gene rearrangements are also found in a small subset of NSCLC and can be targeted by specific drugs.
  4. MET (mesenchymal-epithelial transition factor) – MET gene amplification or mutations are found in a subset of NSCLC and may confer resistance to EGFR-targeted therapies.
  5. PD-L1 (programmed death-ligand 1) – PD-L1 expression is a biomarker that can help predict response to immunotherapy in NSCLC.

By analyzing these specific genetic mutations and biomarkers, the Lung Cancer Panel 4 can help guide treatment decisions and improve patient outcomes.

Test Name Lung Cancer Panel 4 EGFRALK1ROS1METPD L1 Test
Components Paraffin embedded tissue blocks
Price 6000.0 AED
Sample Condition Tumor tissue
Report Delivery 5-7 days
Method FISH,Sanger Sequencing
Test type Genetics
Doctor Oncology
Test Department:
Pre Test Information Lung Cancer Panel 4 EGFR,ALK1,ROS1,MET,PD L1] can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

The Lung Cancer Panel 4 is a diagnostic test that analyzes five specific genetic mutations and biomarkers associated with lung cancer. The panel includes the following:

1. EGFR (epidermal growth factor receptor) – EGFR mutations are found in a significant number of non-small cell lung cancers (NSCLC) and can be targeted by specific drugs.

2. ALK1 (anaplastic lymphoma kinase) – ALK1 gene rearrangements are found in a small subset of NSCLC and can also be targeted by specific drugs.

3. ROS1 (c-ros oncogene 1) – ROS1 gene rearrangements are also found in a small subset of NSCLC and can be targeted by specific drugs.

4. MET (mesenchymal-epithelial transition factor) – MET gene amplification or mutations are found in a subset of NSCLC and may confer resistance to EGFR-targeted therapies.

5. PD-L1 (programmed death-ligand 1) – PD-L1 expression is a biomarker that can help predict response to immunotherapy in NSCLC.

By analyzing these specific genetic mutations and biomarkers, the Lung Cancer Panel 4 can help guide treatment decisions and improve patient outcomes.